Found 15 articles for: "halo"
Patient Perspectives and Attitudes Toward the Diagnostic Process for Central Centrifugal Cicatricial Alopecia
March 2026 | Volume 25 | Issue 3 | Features | 282 | Copyright © March 2026
Halo Seborrheic Keratosis in a Patient of Color With Vitiligo
January 2026 | Volume 25 | Issue 1 | Case Reports | 95 | Copyright © January 2026
A 73-year-old woman with Fitzpatrick skin type V presented with a long-standing brownish-black, three-tone macule on the right anterior thigh that developed a sharply demarcated depigmented halo....
Read MoreHalobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance
August 2025 | Volume 24 | Issue 8 | Original Article | 752 | Copyright © August 2025
Scalp involvement in plaque psoriasis is accompanied by itching and scaling that reduce quality of life and exacerbate psoriatic-associated hair loss. Challenges for the topical treatment of scal...
Read MoreClinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis
June 2025 | Volume 24 | Issue 6 | Original Article | 590 | Copyright © June 2025
Background: Hyperkeratotic psoriatic plaques, characterized by considerable elevation and scaling, present treatment challenges with topical therapy. This post hoc analysis of tw...
Read MoreHalobetasol Propionate 0.01% and Tazarotene 0.045% Lotion With a Ceramide-Containing Moisturizer in Adults With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 50 | Copyright © February 2024
Introduction: Moisturizers are often used as adjuvant therapy for psoriasis to assist with rehydration and skin barrier restoration. Fixed-combination halobetasol propionate 0.01...
Read MoreMultiple Halo Nevi Induced by Intense Sun Exposure
December 2023 | Volume 22 | Issue 12 | Case Reports | e31 | Copyright © December 2023
We present the case of a 38-year-old male who reported to our practice with multiple newly developed halos around 26 existing nevi on his trunk. The halo nevi developed after the patient, who liv...
Read MoreBreaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene
March 2023 | Volume 22 | Issue 3 | Original Article | 247 | Copyright © March 2023
Topical therapies are commonly used to treat psoriasis, either as monotherapy for milder disease or as adjuncts to systemic and biologic drugs. Topical steroids and tazarotene are both options fo...
Read MoreMeeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion
February 2023 | Volume 22 | Issue 2 | Original Article | 132 | Copyright © February 2023
Discordance between patient and clinician treatment goals and expectations can present a challenge to implementation of effective therapeutic plans. Because topical treatments are commonly used for pl...
Read MoreAn Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis
November 2021 | Volume 20 | Issue 11 | Original Article | 1191 | Copyright © November 2021
Up to 80% of individuals with plaque psoriasis have scalp involvement, which can have a significant impact on the quality of life of affected individuals. Despite advancements in psoriasis therapeutic...
Read MoreFixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%–5% Affected Body Surface Area
August 2021 | Volume 20 | Issue 8 | Original Article | 829 | Copyright © August 2021
Introduction: Patients with psoriasis and low body surface area (BSA) involvement often experience substantially reduced quality of life and may be candidates for topical therapies. F...
Read MoreSuccessful Treatment of Lichen Amyloidosis Using a Fixed Combination of Halobetasol-Propionate and Tazarotene Lotion
March 2021 | Volume 20 | Issue 3 | Case Reports | 336 | Copyright © March 2021
Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants
March 2021 | Volume 20 | Issue 3 | Original Article | 252 | Copyright © March 2021
Background: Psoriasis is a chronic, inflammatory disease that may differ in prevalence and clinical presentation among patients from various racial and ethnic groups. Two phase 3 stud...
Read MoreSafety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials
October 2018 | Volume 17 | Issue 10 | Original Article | 1062 | Copyright © October 2018
BACKGROUND: Topical corticosteroids (TCS) are the mainstay of psoriasis treatment; long-term safety concerns limiting con...
Read MoreRapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination
August 2018 | Volume 17 | Issue 8 | Original Article | 863 | Copyright © August 2018
Background: Psoriasis is a chronic condition often managed with topical therapy. Patients have high expectations about the speed at which ...
Read MoreHalobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
July 2018 | Volume 17 | Issue 7 | Original Article | 723 | Copyright © July 2018
Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Topical corticosteroids (TCS...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
